EYP 001

Drug Profile

EYP 001

Alternative Names: EYP001; EYP001a

Latest Information Update: 01 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Poxel
  • Developer ENYO Pharma; Poxel; PRA Health Sciences
  • Class Antivirals; Small molecules
  • Mechanism of Action Farnesoid X-activated receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hepatitis B

Most Recent Events

  • 21 Sep 2017 Phase-I clinical trials in Hepatitis B in Australia (PO)
  • 21 Sep 2017 Enyo Pharma initiates enrolment in a phase I trial for Hepatitis B in Australia, Netherlands (PO) (NCT03272009)
  • 14 Jun 2017 Pharmacokinetics, Pharmacodynamics and Adverse events data from a phase Ia trial released by ENYO Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top